Abstract 5321
Background
The aim of this study was to assess Progression Free Survival (PFS), Safety and Quality of Life (QoL) in subgroups of varying hepatic burden in the NETTER-1 study population.
Methods
Patients (pts) were randomized to receive either 177Lu-DOTATATE (Lu)(n = 117) or high-dose octreotide (Oct) (n = 114). The liver tumor burden (LTB) was defined as tumor volume/total liver volume by CT, and categorized as low (<25%), moderate (25-50%), and high (>50%). PFS, QoL and hepatotoxicity were assessed based on baseline LTB. QoL was analysed using EQRTC QLQC 30 and G.I. NET 21 questionnaires completed at baseline and every 12 weeks thereafter for low and moderate/high LTB subgroups. Deterioriation was defined if the score decreased by ≥ 10 points at any time point after baseline. Time to deterioration (TTD) was defined as the time from randomization to the first QoL deterioration.
Results
Median PFS (months) in Lu vs Oct was 28.35 vs 11.04 in low (HR = 0.218, 95% CI 0.120 to 0.394); Not Reached (NR) vs 8.67 in moderate (HR = 0.202, 95% CI 0.077 to 0.525); 19.38 vs 5.52 in high LTB (HR = 0.193, 95% CI 0.079 to 0.474), respectively. Median TTD (months) for Global Health Status was 28.81 vs 6.11 in low (HR = 0.376, 95% CI 0.196 to 0.720); NR vs 5.98 in moderate/high LTB (HR = 0.453, 95% CI 0.178 to 1.152). In Lu arm, Grade 3/4 (CTCAE v 4.03) AST and ALT toxicities occurred in the low LTB in 2 and 3 patients, and in the high LTB group in 3 and 1 patients, respectively. Grade 3/4 hyperbilirubinemia occurred in one patient from the low LTB and one from the moderate LTB group. All liver function tests abnormalities were resolved without sequela. There were no high grade ALT, AST and Biliriubin toxicities in Oct arm.
Conclusions
177Lu-DOTATATE treatment demonstrated significant PFS improvement regardless of the extent of baseline liver tumor burden in patients with well-differentiated, metastatic midgut NET. Clinically significant liver function test abnormalities were rare, were not associated with high liver tumor burden, and resolved without sequela. The analysis shows that 177Lu-DOTATATE treatment also provides quality of life benefit regardless of baseline liver tumor burden.
Clinical trial identification
NCT01578239.
Legal entity responsible for the study
Advanced Accelerator Applications, a Novartis company.
Funding
Advanced Accelerator Applications, a Novartis company.
Editorial Acknowledgement
Disclosure
B. Polack, B. He, D. Barton, P. Santaro: Employment: Advanced Accelerator Applications. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract